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Abstract
Background Millions of patients receive vitamin K antag-
onist (VKA) therapy worldwide. Annually 0.2–1 % of all
VKA users develops an intracranial hemorrhage (ICH).
Prothrombin complex concentrate (PCC) is administered to
restore the INRB 1.5 in an attempt to limit hematoma growth.
In order to facilitate PCC dosing, our hospital recently changed
from a variable dose based on bodyweight, baseline- and tar-
get-INR, to a fixed 1000 IU fIX PCC dosing protocol for ICH.
Methods In a before and after design, we compared
successful achievement of an INR B 1.5 with a fixed
dosing strategy versus the variable dosing strategy of PCC
in patients presenting with intracranial bleeding compli-
cations of VKA. Data of the two cohorts of patients were
retrospectively collected from medical records.
Results A median dosage of 1750 IU was given per patient
in the variable dose group (n = 25) versus 1000 IU in the fixed
dose group (n = 28). In the intention-to-treat analysis, 96 %
achieved an INRB 1.5 after an initial dose in the variable dose
cohort compared to 68 % in the fixed dose cohort (p = 0.01).
An additional dose was given in 2 (8 %) versus 9 (32 %)
patients, respectively (p = 0.04). The median door-to-PCC-
order time was 42 versus 32 min (p = 0.37) and the door-to-
needle time was 81, respectively 60 min (p = 0.42).
Conclusion The fixed dose protocol necessitates addi-
tional PCC infusions more frequently to achieve a target
INR B 1.5. Door-to-order and door-to-needle time were
shorter but, in this small cohort, not significantly so. The
effect on clinical outcome remains unknown.
Keywords Intracranial hemorrhage  Hemostasis 
International normalized ratio 
Prothrombin complex concentrate  Vitamin K antagonist
Introduction
Vitamin K antagonists (VKA) are used worldwide in pri-
mary and secondary prophylaxis of thromboembolic events.
A major risk of VKA is the occurrence of intracranial
hemorrhage (ICH). ICH is seen in 0.2–1.0 % of the anti-
coagulated population annually [1, 2]. Approximately 20 %
of all ICH is associated with use of anticoagulants [1–3],
with high mortality ranging from 40 to 60 % [4]. Rapid
reversal of anticoagulant therapy in the management of ICH
is crucial to reduce the risk of hematoma enlargement [5–7],
which is in turn associated with poor outcome [8, 9].
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Current American and European guidelines recommend
administration of four-factor prothrombin complex concentrate
(PCC) to reverse VKA therapy in ICH (level of evidence: ‘C:
expert opinion’ and ‘very low’, respectively), however, without
consensus regarding PCC dose calculation or the target inter-
national normalized ratio (INR) to be achieved [10, 11]. In
terms of speed of administration, a fixed PCC dose instead of
the conventional variable dose eliminates the need for dose
calculation based on patient-specific variables. This is hypoth-
esized to promote an earlier start of hemostasis restoration,
favoring limitation of hematoma enlargement in ICH.
A hospital-wide implementation of a fixed PCC dosing
regimen of 1000 IU fIX (factor IX), corresponding with
40 ml Cofact (Sanquin, Amsterdam), was introduced for
VKA-associated bleeding complications in a Dutch teach-
ing hospital. Several important arguments have advocated
the use of a fixed dose: easier administration requiring no
complex tables and input variables and reduction of door-
to-needle time. Both factors are hypothesized to contribute
to a better clinical outcome [7].
In the present study, we retrospectively compared
achievement of the target INR (B1.5) of the fixed dosing
strategy versus the variable dosing strategy of PCC in
patients presenting with a VKA-associated ICH. As timely
management of ICH and consequently rapid reversal of
anticoagulation are crucial in outcome in ICH, the door-to-
needle time and time to achievement of target INR were of
special interest and are included as secondary endpoints.
Patients and Methods
Overall Study Design
This is a retrospective study comparing the effect of two
different PCC dosing strategies in a before and after design.
The setting is a large teaching hospital that serves as
regional neuro-trauma center. Here, a change in dosing
protocol for PCC in VKA-related bleeding emergencies was
introduced in November 2013. Before this date, the man-
ufacturer’s recommended variable dose was used for PCC
in VKA-related ICH. From November 2013, the variable
dose was replaced by a fixed PCC dose for this indication.
The local Medical Ethics Committee reviewed the study
protocol prior to data collection (METC Zuid Holland
West, No. 14-061) and decided that, according to Dutch
law, full review and informed consent were not required for
this retrospective study.
Patient Population
Patients were eligible for inclusion if they were at least
18 years of age and presented with ICH (primary or
trauma-related), while on VKA therapy, for which PCC
was administered. The inclusion time was from 1 January
2013 to 1 August 2014. November 2013 was considered as
a protocol transition month, and therefore all eligible
patients treated in this month were excluded. Patients were
only included once in this study.
Study Treatment
Until November 2013, patients were treated with a variable
dose of PCC according to manufacturer’s specifications.
This comprised a dose calculation based on patient body-
weight, initial INR and desired target INR (B1.5). If target
INR was not achieved when follow-up INR was assessed,
additional dosing was left to the treating physicians dis-
cretion. After the change of protocol, patients were treated
with a fixed dose of 1000 IU fIX PCC, followed by follow-
up INR-assessment. If the target INR of B1.5 was not
achieved, another 500 IU fIX PCC was administered.
A single brand of PCC was used within this timeframe,
Cofact (Sanquin BV, Amsterdam, the Netherlands). This
product contains factors II, VII, IX and X, as well as protein
C and S without containing activated factors or heparin.
Study Outcomes
The primary endpoint of the study was achievement of
INR B 1.5. Secondary end points included the time
between presentation at the emergency department and the
PCC order (door-to-order time), the time between entry
into the emergency department and start of PCC infusion
(door-to-needle time), the proportion of patients that nee-
ded an additional dose of PCC, the median INR after initial
PCC administration, degree of disability according to the
modified Rankin Scale (mRS) at discharge, duration of stay
at the emergency department, duration of intensive care/
stroke care unit stay, total duration of hospital stay, in-
hospital thromboembolic or rebleeding events and mortal-
ity in-hospital and at 30 days after PCC administration.
Data Collection
Both digital medical records from the hospital information
system and paper medical records were retrieved for data
collection. Data was collected regarding baseline charac-
teristics (age, gender, weight, baseline INR, type of VKA
and ICH type), primary outcome (follow-up INR after PCC
administration up until 6 h after start of infusion or before
additional PCC dose, whichever was first) and secondary
outcomes.
Two authors (RA and IM) classified modified Rankin
Score at discharge independently and reached consensus in
case of disagreement, using reports in medical records and
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blinded from treatment regimen. Mortality status at
30 days after PCC administration was collected via general
practitioners or nursing home doctors if this could not be
obtained from the hospital information system.
Statistical Analyses
Statistical analysis was performed using SPSS 22.0 (IBM
Corporation, New York). All data were analyzed according
to the intention-to-treat principle and findings were sub-
sequently verified by performing a per-protocol analysis.
For all outcome parameters, quantitative data was analyzed
with Mann–Whitney U tests and categorical data with
Fisher’s exact tests or Chi square tests.
Results
A total of 72 patients were considered for this study of
which 53 met all inclusion criteria. Of these, 25 patients
were included in the variable dose group and 28 patients in
fixed dose group, as is seen in Fig. 1. Baseline character-
istics are specified in Table 1. Both groups had similar
baseline characteristics. The median age was 77 years and
more than 70 % of the patients received VKA as part of
atrial fibrillation therapy. The bleeding was intra-
parenchymal in approximately half of the patients; cause of
bleeding was in 40 % of the patients related to trauma
versus spontaneous bleeds in 60 %. Median baseline INR
was also equivalent in both groups.
Successful achievement of INR B 1.5 after the initial
PCC dose was seen in 96 % of the patients in the variable
dose group versus 68 % of the patients in the fixed dose
group (Fig. 2). Median follow-up INR was significantly
higher in the fixed dose group as compared to the variable
dose group. Patients in the variable dose group received a
median initial dose of 1750 IU, in the fixed dose group,
1000 IU (see Table 2) fIX. Two patients (8 %) (of which
one had already achieved the target INR) received an
additional dose in the variable dose group, versus nine
patients (32 %) in the fixed dose group. The median total
PCC dose did not differ from the median initial dose
because more than half of the patients in each group
reached the target INR with the initial dose.
There was no significant difference in time to treatment
between the variable and fixed dose groups in door-to-order
or door-to-needle time (Table 3). Data about mRS, mor-
tality and duration of stay is also presented in Table 3. No
rebleeding events were registered in both groups. Two
patients in the variable dose group (8.3 %) developed a
Fig. 1 Flow chart of patient
inclusion. Seventy-two patients
received PCC for treatment of a
VKA-associated ICH between
January 2013 and August 2014.
Six patients that presented with
ICH in November 2013 were
excluded, as this was the
protocol transition month. 30
eligible patients remained in the
group before November 2013
and 36 patients after. In both
cohorts 4 patients were
excluded due to a missing
follow-up INR (lost to follow-
up), while PCC dose could not
be retrieved for 1 patient before
versus 4 patients after
November 2013. This resulted
in 25 inclusions in the variable
dose group and 28 inclusions in
the fixed dose group
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thromboembolic event characterized by worsening of
hemiparesis on day 2 and day 4 after PCC administration.
Subsequent CT-scans confirmed recent ischemia. The
patients had a baseline INR of 2.8 and 3.6, which after PCC
administration both reduced to 1.3. No thromboembolic
events were seen in the fixed dose group.
Post hoc, we performed a subgroup analysis of patients
with a baseline INR B 4. In the variable dose group 19 out
of 19 patients (100 %) with a baseline INR below 4
achieved the target INR, compared to 16 out of 18 (89 %)
patients in the fixed dose group (p = 0.230). Median initial
PCC dose was 1750 IU per patient in the variable dose
group versus 1000 IU in the fixed dose group (p = 0.002).
Discussion
This retrospective study shows that an initial fixed dose of
1000 IU fIX PCC is inferior in achieving the target INR of
B1.5 in comparison to the variable dose calculated from
bodyweight, baseline INR and target INR.
The choice of a fixed dose of 1000 IU might have been
too low, as the target-INR achievement rate of the initial
dose was only 68 %. Assuming an average bodyweight of
75 kg in our population, a median dose of 13 IU/kg can be
calculated in the fixed dose group. In comparison, a pre-
vious French prospective observational multicenter study
Table 1 Baseline characteristics of the variable and fixed dose group
Variable dose group Fixed dose group p value
n = 25 n = 28
Gender (female); n (%) 12 (48 %) 14 (50 %) 1.000
Age (years); median (min–max) 77 (50–91) 77 (52–94) 1.000
Weight (kg); median (min–max) 79 (61–139) 73 (45–176) 0.211
INR; median (min–max) 3.1 (1.8–9) 3.3 (1.7–9) 0.175
VKA type
Acenocoumarol; n (%) 6 (24 %) 5 (18 %) 0.737
Phenprocoumon; n (%) 19 (76 %) 23 (82 %)
VKA indication
Arrhythmia; n (%) 18 (72 %) 23 (82 %) 0.485
Deep vein thrombosis (prophylaxis); n (%) 7 (28 %) 4 (15 %)
Artificial heart valve; n (%) 0 (0 %) 1 (4 %)
ICH cause (traumatic); n (%) 11 (39 %) 10 (40 %) 1.000
ICH type
IPH; n (%) 11 (44 %) 16 (57 %) 0.562
SDH; n (%) 8 (32 %) 4 (14 %)
SAH; n (%) 4 (16 %) 3 (11 %)
Other; n (%) 2 (8 %) 5 (18 %)
INR international normalized ratio, VKA vitamin K antagonist, ICH intracranial hemorrhage; IPH intraparenchymal hemorrhage, SDH subdural
hemorrhage, SAH subarachnoid hemorrhage
Fig. 2 INR before and after initial PCC dose in the variable and fixed
dose group. Boxes span the interquartile range with median, minimum
and maximum values indicated by horizontal bars. The dashed line
visualizes the achievement of target-INR B 1.5
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in ICH reported the use of a variable dose of 25 IU/kg,
leading to an achievement rate of 76.5 % [12]. In contrast,
another French prospective, but randomized, multicenter
study in ICH found 100 % achievement in both 25 and
40 IU/kg treatment arms [13]. Our variable dose group
demonstrated 96 % achievement with a median dose of
23 IU/kg bodyweight. Therefore, a higher initial dose in a
fixed dose regimen might lead to achievement rates com-
parable to those found in variable dose regimens.
When restricting to patients with a baseline INR B 4.0,
post hoc analysis showed no significant difference between
target INR achievement rates of variable dose and fixed
dose groups. These achievement rates were acquired with a
large between-group difference of 750 IU in median
required PCC dose. Importantly, this has to be interpreted
with caution, as it was a post hoc analysis using a small
subgroup.
We found shorter, but not statistically significant so,
door-to-order and door-to-needle times for the fixed dose
group. As this study was not powered to demonstrate a
difference, this could very well be a power issue requiring
further investigation. In comparison, a significant and
clinically relevant reduction of door-to-needle time was
observed in a previous prospective cohort of extracranial
bleeds when using a fixed dose. Median time to infusion
reduced from 160 min in the variable dose group to
130 min in the fixed dose group. Although follow-up INR
was higher after an initial dose as compared to the variable
dose, clinical outcome was non-inferior or even better in
the fixed dose group [14]. It was therefore hypothesized
that a shorter door-to-needle time could be related to a
comparable of even better clinical outcome.
Data on clinical outcome in our set of patients was
however not recorded systematically trough functional
outcome scales [i.e., modified Rankin Scale (mRS), Barthel
Index (BI)]. mRS at discharge was assessable retrospec-
tively from discharge reports. However follow-up mRS
could not be determined because a large number of patients
had no records on follow-up visits. Glasgow coma scores
were recorded systematically, but frequently clouded by
missing verbal scores due to aphasia and/or intubation.
These impairments on verbal communication are inherent
to ICH and lead to coma scores unrepresentative of the
actual coma grade. In future (prospective) studies on this
subject, data should be collected accordingly.
The strength of this study is that it used real life data on
fixed dosing of PCC in ICH. Furthermore, the data of PCC
dosing in ICH was well documented, therefore contributing
to the quality of the study. This study also has important
limitations. A main limitation is the small sample size,
Table 2 Results on primary outcome of both variable and fixed dose group
Variable dose group (n = 25) Fixed dose group (n = 28) p value
INR B 1.5 after initial PCC dose; n (%) 24 (96 %) 19 (68 %) 0.013
Additional dose received; n (%) 2 (8 %) 9 (32 %) 0.043
INR after initial dose; median (min–max) 1.3 (1–1.9) 1.4 (1.2–2) 0.001
Initial PCC dose (IU); median (min–max) 1750 (1000–2500) 1000 (1000–2500) 0.000
Total PCC dose (IU); median (min–max) 1750 (1000–2500) 1000 (1000–3000) 0.005
INR international normalized ratio, PCC prothrombin complex concentrate
Table 3 Results on secondary outcome parameters for both variable and fixed dose group
Variable dose group Fixed dose group p value
(n = 25) (n = 28)
Door-to-order time (min); median (min–max) 42 (0–207) 32 (3–211) 0.370
Door-to-needle time (min); median (min–max) 81 (33–231) 60 (24–251) 0.420
Modified Rankin Score B3 at discharge; n/total (%) 11/21 (52 %) 10/23 (44 %) 0.773
Mortality
At discharge; n (%) 3 (12 %) 6 (22 %) 0.474
At 30 days after PCC treatment; n (%) 4 (16 %) 7 (25 %) 0.509
Duration of stay
Emergency department (h); median (min–max) 2.7 (0–4.8) 3 (0–7.4) 0.232
Intensive/stroke care unit (days); median (min–max) 1.0 (0–17) 2.0 (0–14) 0.088
Total stay (days); median (min–max) 8 (1–43) 11.5 (1–52) 0.643
Mortality status at discharge and at 30 days after PCC treatment was known for all included patients. Door-to-order and door-to-needle time was
unknown for 3 patients in the variable dose group and for 3 respectively 5 patients in the fixed dose group
68 Neurocrit Care (2017) 26:64–69
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therefore lacking power to draw conclusions from data of
the secondary endpoints. The sample size was however
sufficient to demonstrate a significant difference in the
primary outcome, achievement of target-INR. Another
limitation is the retrospective nature of our study, resulting
in the absence of parameters necessary for comparison of
clinical outcome, such as follow-up CT scan, stroke clas-
sification according to the NIH Stroke Scale, BI and
follow-up mRS scores.
Based on the findings of this first small retrospective
study, implementation of a fixed dose of 1000 IU fIX
cannot be recommended for VKA-related ICH. A fixed
dose does have important advantages, compared to variable
dose regimens, but 1000 IU is probably too low. Subse-
quent studies should include systematic evaluation of
clinical outcome, in addition to INR results.
Conclusion
By applying a fixed PCC dose (1000 IU fIX) target-INR
was achieved in significantly less patients compared to a
weight and INR-based PCC dose regimen for treatment of
VKA-related ICH. Consequently, the fixed dose protocol
necessitated additional PCC dosing to obtain the target-
INR more frequently. The time between door-to-order and
door-to-needle was not significantly shorter with the fixed
dose protocol. The effect of PCC dose and target-INR on
clinical outcome remains unclear.
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